Abstract | BACKGROUND: RESULTS: Our study revealed that sulforaphane displayed antitumor activity against NSCLC cells both in vitro and in vivo. The sensitivity of NSCLC cells to sulforaphane appeared to positively correlate with the inhibition of EGFR-related signaling, which was attributed to the increased proteasomal degradation of EGFR. Combined treatment of NSCLC cells with sulforaphane plus another HSP90 inhibitor (17-AAG) enhanced the inhibition of EGFR-related signaling both in vitro and in vivo. CONCLUSIONS: We have shown that sulforaphane is a novel inhibitory modulator of EGFR expression and is effective in inhibiting the tumor growth of EGFR-TKI-resistant NSCLC cells. Our findings suggest that sulforaphane should be further explored for its potential clinical applications against NSCLC.
|
Authors | Chi-Yuan Chen, Zhu-Yun Yu, Yen-Shu Chuang, Rui-Mei Huang, Tzu-Chien V Wang |
Journal | Journal of biomedical science
(J Biomed Sci)
Vol. 22
Pg. 38
(Jun 03 2015)
ISSN: 1423-0127 [Electronic] England |
PMID | 26036303
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Isothiocyanates
- Sulfoxides
- EGFR protein, human
- ErbB Receptors
- sulforaphane
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Carcinoma, Non-Small-Cell Lung
(physiopathology)
- Cell Line, Tumor
- ErbB Receptors
(genetics, metabolism)
- Humans
- Isothiocyanates
(pharmacology)
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Random Allocation
- Signal Transduction
(drug effects)
- Sulfoxides
|